Basic Information
| ID | DRAMP21238 |
| Sequence | WKRWVQRWKRFLR |
| Length | 13 |
| Name | FK13-a5 (Derived from FK13) |
| Source | Synthetic construct |
| Activity | Antimicrobial, Antibacterial, Anti-Gram+, Anti-Gram- |
| Pathogen | [Ref.28161291] Gram-positive bacteria : Bacillus subtilis(KCTC 3068)(MIC=4 μM), Staphylococcus epidermidis(KCTC 1917)(MIC=4 μM), Staphylococcus aureus(KCTC1621)(MIC=2 μM);##Gram-negative bacteria : Escherichia coli(KCTC 1682)(MIC=4 μM), Pseudomonas aeruginosa(KCTC 1637)(MIC=16 μM), Salmonella typhimurium(KCTC 1926)(MIC=2 μM) |
| Hemolytic Activity | [Ref.28161291] HC50=230.0 μM against human red blood cells |
| Cytotoxicity | [Ref.28161291] The cell viability of mouse macrophage RAW264.7 induced by FK13-a5 is 105.3%, 103.9%, 97.1%, 94.0%, 47.5% and 44.2% at peptide concentrations of 1.25, 2.5, 5, 10, 20 and 40 μM.## The cell viablity of human keratinocyte HaCaT induced by FK1 |
| N-terminal Modification | Free |
| C-terminal Modification | Amidation |
| Linear/Cyclic/Branched | Linear |
| Uniprot |
|
| PDB |
|
| 3D View | |
|---|
| PDB Download | Download PDB Predicted by Alphafold2 |
|---|
| PubMed ID | 28161291 |
|---|